Oxy-cyanoquinolinone PDE9 inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10370337
APP PUB NO 20180258046A1
SERIAL NO

15745850

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • MERCK SHARP & DOHME CORP.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Converso, Antonella Elkins Park, US 15 56
Kaufman, Mildred L Schwenksville, US 5 26
Rodzinak, Kevin Valdosta, US 3 12

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 6, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 6, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00